ctDNA for Progression on Fulvestrant in ER+ Breast Cancer ctDNA for Progression on Fulvestrant in ER+ Breast Cancer

Does ctDNA prove an effective indicator of early progression on fulvestrant therapy in patients with advanced ER+ breast cancer?Journal of the National Cancer Institute
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news